BR112022002392A2 - Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos - Google Patents
Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usosInfo
- Publication number
- BR112022002392A2 BR112022002392A2 BR112022002392A BR112022002392A BR112022002392A2 BR 112022002392 A2 BR112022002392 A2 BR 112022002392A2 BR 112022002392 A BR112022002392 A BR 112022002392A BR 112022002392 A BR112022002392 A BR 112022002392A BR 112022002392 A2 BR112022002392 A2 BR 112022002392A2
- Authority
- BR
- Brazil
- Prior art keywords
- state forms
- solid state
- neopentylamino
- pentanamide
- tetrahydronaphthalen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos. a presente descrição refere-se a: a) formas em estado sólido de sais de bromidrato do composto 1; b) composições farmacêuticas compreendendo uma ou mais formas em estado sólido de sais de bromidrato do composto 1 e, opcionalmente, um veículo farmaceuticamente aceitável; c) métodos de tratamento de tumores ou cânceres pela administração de uma ou mais formas em estado sólido de sais de bromidrato do composto 1 a um indivíduo que delas necessite; e d) métodos para a preparação de formas em estado sólido do composto 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/045948 WO2021029854A1 (en) | 2019-08-09 | 2019-08-09 | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022002392A2 true BR112022002392A2 (pt) | 2022-04-26 |
Family
ID=67734850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022002392A BR112022002392A2 (pt) | 2019-08-09 | 2019-08-09 | Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP4010322A1 (pt) |
JP (1) | JP2022553479A (pt) |
KR (1) | KR20220062510A (pt) |
CN (1) | CN114555562A (pt) |
AR (1) | AR119614A1 (pt) |
AU (1) | AU2019461090A1 (pt) |
BR (1) | BR112022002392A2 (pt) |
CA (1) | CA3150424A1 (pt) |
CO (1) | CO2022002731A2 (pt) |
IL (1) | IL290428A (pt) |
MX (1) | MX2022001743A (pt) |
PE (1) | PE20221252A1 (pt) |
WO (1) | WO2021029854A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20230614A1 (es) * | 2020-03-13 | 2023-04-14 | Springworks Therapeutics Inc | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas |
US11504354B1 (en) * | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
WO2023096954A1 (en) | 2021-11-23 | 2023-06-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of nirogacestat salts |
WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20084420B (en) * | 2004-03-23 | 2008-07-10 | Pfizer Prod Inc | Use of imidazole compounds for the treatment of neurodegenerative disorders |
US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
WO2019053727A1 (en) * | 2017-09-18 | 2019-03-21 | Ramot At Tel-Aviv University Ltd. | REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH |
-
2019
- 2019-08-09 WO PCT/US2019/045948 patent/WO2021029854A1/en unknown
- 2019-08-09 MX MX2022001743A patent/MX2022001743A/es unknown
- 2019-08-09 BR BR112022002392A patent/BR112022002392A2/pt unknown
- 2019-08-09 AU AU2019461090A patent/AU2019461090A1/en active Pending
- 2019-08-09 EP EP19758589.6A patent/EP4010322A1/en active Pending
- 2019-08-09 PE PE2022000224A patent/PE20221252A1/es unknown
- 2019-08-09 CN CN201980100044.2A patent/CN114555562A/zh active Pending
- 2019-08-09 KR KR1020227007648A patent/KR20220062510A/ko unknown
- 2019-08-09 CA CA3150424A patent/CA3150424A1/en active Pending
- 2019-08-09 IL IL290428A patent/IL290428A/en unknown
- 2019-08-09 JP JP2022508525A patent/JP2022553479A/ja active Pending
-
2020
- 2020-08-06 AR ARP200102241A patent/AR119614A1/es unknown
-
2022
- 2022-03-09 CO CONC2022/0002731A patent/CO2022002731A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022553479A (ja) | 2022-12-23 |
CN114555562A (zh) | 2022-05-27 |
AU2019461090A1 (en) | 2022-03-17 |
PE20221252A1 (es) | 2022-08-16 |
KR20220062510A (ko) | 2022-05-17 |
IL290428A (en) | 2022-07-01 |
CO2022002731A2 (es) | 2022-05-20 |
WO2021029854A1 (en) | 2021-02-18 |
MX2022001743A (es) | 2022-05-10 |
AR119614A1 (es) | 2021-12-29 |
EP4010322A1 (en) | 2022-06-15 |
CA3150424A1 (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022002392A2 (pt) | Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos | |
PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
EP3569601A3 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
CR20230310A (es) | Inhibidores de prmt5 | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
MY197785A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
NI202100031A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
BR112017021669A2 (pt) | formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações | |
BR112019000509A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica |